2021
Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2014
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Annals Of Surgical Oncology 2014, 21: 704-716. PMID: 24515565, DOI: 10.1245/s10434-014-3481-4.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceInvasive breast cancerBreast cancerClear marginsRate of IBTRRisk of IBTRRadiation Oncology consensus guidelinesSurgical Oncology–American SocietyMargin widthMultidisciplinary consensus panelOptimal margin widthBreast tumor recurrenceExtensive intraductal componentBreast conserving surgeryBreast-conserving surgeryRe-excision ratesHealth care costsUnfavorable biologyEndocrine therapyMultidisciplinary therapyRadiation boostYounger patientsIntraductal componentLobular cancerNegative margins
2012
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology
2011
Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance Study
Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL, Pensa MA, Gonsalves L, Stevens RG, Runowicz CD. Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance Study. Clinical Breast Cancer 2011, 11: 332-341. PMID: 21729670, PMCID: PMC4459583, DOI: 10.1016/j.clbc.2011.04.004.Peer-Reviewed Original ResearchConceptsConnecticut Tumor RegistryTN breast cancerBlack patientsBreast cancerSurvival disparitiesWhite patientsLocal diseaseHER2 statusTN statusNational Cancer Institute's Surveillance EpidemiologyPrimary invasive breast cancerTriple-negative breast cancerAdvanced breast cancerInvasive breast cancerTriple-negative subtypeRisk of deathStatewide cancer registryAdvanced diseaseDuctal tumorsLobular cancerPrognostic roleTumor RegistryCancer RegistryHistologic subtypeRegional disease
2009
Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy.
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research 2009, 69: 959-959. DOI: 10.1158/0008-5472.sabcs-09-959.Peer-Reviewed Original ResearchContralateral breast cancerOperable breast cancerBreast conservationBreast cancerLocal therapyBRCA1/2 mutationsDistant failureClinical characteristicsBRCA1/2 carriersLocal failureBC-specific survivalDeleterious BRCA1/2 mutationsLocal treatment optionsInvasive lobular cancerGermline BRCA1/2 mutationsSignificant predictorsSignificant differencesOnly significant predictorAdjuvant chemotherapyBCT patientsOverall survivalContralateral breastLobular cancerLocal recurrenceRandomized trials
1998
Metastatic Breast Cancer Masquerading as Gastrointestinal Primary
Schwarz R, Klimstra D, Turnbull A. Metastatic Breast Cancer Masquerading as Gastrointestinal Primary. The American Journal Of Gastroenterology 1998, 93: ajg199828. PMID: 9448188, DOI: 10.1111/j.1572-0241.1998.111_c.x.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerGastrointestinal primaryHistory of mammary carcinomaDiagnosis of metastatic breast cancerGross cystic disease fluid proteinCystic disease fluid proteinBreast biopsy materialHeme-positive stoolsInfiltrating lobular cancerHormone receptor statusInfiltrating ductal cancerCases of gastric tumorsSystemic cytotoxic therapyTime of diagnosisLevel of suspicionBreast cancer histologyTumor presentationReceptor statusCytotoxic therapyLobular cancerSurgical resectionSystemic metastasesDuctal cancerEpigastric pain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply